Hydrocortisone Medo (Hydrocortisone)

Hydrocortisone Medo is indicated for several acute and chronic medical situations where rapid glucocorticoid activity is required.

• Replacement therapy in primary or secondary adrenal insufficiency.
• Management of circulatory shock, including septic, anaphylactic, or adrenal crisis.
• Treatment of severe inflammatory conditions such as vasculitis, severe dermatitis, or pulmonary inflammation.
• Rapid control of acute allergic reactions, including angioedema and bronchospasm.
• Adjunctive therapy in postoperative or trauma patients to reduce systemic inflammation.
• Support of endocrine function during abrupt withdrawal of long‑term corticosteroid therapy.
• Prevention of adrenal crisis in patients undergoing major surgery or severe stress.

• Hydrocortisone Medo acts as an agonist at intracellular glucocorticoid receptors. After crossing cell membranes, the drug binds to the receptor complex, translocates to the nucleus, and modulates gene transcription. This results in decreased synthesis of pro‑inflammatory cytokines, inhibition of phospholipase A2, and reduced expression of adhesion molecules, collectively producing anti‑inflammatory and immunosuppressive effects. It also influences carbohydrate metabolism and vascular tone, contributing to its role in shock management.

Adverse reactions to Hydrocortisone Medo can vary in frequency and severity. The following lists are based on clinical observations and reported case data.

Common

• Transient increase in blood glucose levels.
• Mild electrolyte disturbances such as sodium retention or potassium loss.
• Local irritation or pain at the injection site.
• Headache or dizziness.
• Temporary flushing or warmth sensation.
• Nausea or mild gastrointestinal upset.

Serious

• Severe hypersensitivity reactions, including anaphylaxis.
• Acute adrenal suppression after abrupt discontinuation.
• Significant infection risk due to immunosuppression.
• Gastrointestinal bleeding or ulceration.
• Mood or psychiatric changes, such as depression or psychosis.
• Hypernatremia or fluid retention leading to edema.
• Osteoporosis or bone demineralization with prolonged use.

When prescribing Hydrocortisone Medo, clinicians should evaluate patient history and monitor for conditions that may be aggravated by glucocorticoid therapy.

• Assess for active or latent infections before initiating treatment.
• Use the lowest effective dose for the shortest duration possible.
• Monitor blood glucose and electrolyte levels, especially in diabetic or renal patients.
• Caution in patients with hypertension, heart failure, or a history of peptic ulcer disease.
• Evaluate for potential adrenal suppression in patients receiving long‑term corticosteroids.
• Consider pregnancy and lactation status; benefits must outweigh potential risks.
• Review concomitant medications that may increase glucocorticoid exposure.

Hydrocortisone Medo can alter the pharmacokinetics or pharmacodynamics of several other agents. Awareness of these interactions helps prevent reduced efficacy or increased toxicity.

Avoid

• Strong CYP3A4 inducers such as rifampin, phenytoin, or carbamazepine, which may lower hydrocortisone concentrations.
• Live vaccines, because immunosuppression can diminish vaccine effectiveness and increase infection risk.

Use with caution

• Anticoagulants (e.g., warfarin) – glucocorticoids may enhance anticoagulant effect.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – combined use raises risk of gastrointestinal bleeding.
• Diabetic medications – glucocorticoid‑induced hyperglycemia may require dose adjustment.
• Antihypertensives – fluid retention can counteract blood pressure control.
• Other corticosteroids – additive immunosuppressive effects increase infection risk.